Zurich Cantonal Bank’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.36M | Buy |
4,311
+1,190
| +38% | +$280K | ﹤0.01% | 1357 |
|
|
2026
Q1 | $623K | Sell |
3,121
-72
| -2% | -$14.2K | ﹤0.01% | 1715 |
|
|
2025
Q4 | $604K | Hold |
3,193
| – | – | ﹤0.01% | 1673 |
|
|
2025
Q3 | $566K | Buy |
3,193
+689
| +28% | +$102K | ﹤0.01% | 1667 |
|
|
2025
Q2 | $285K | Sell |
2,504
-12
| -0.5% | -$1.28K | ﹤0.01% | 1981 |
|
|
2025
Q1 | $265K | Buy |
2,516
+117
| +5% | +$13.2K | ﹤0.01% | 1955 |
|
|
2024
Q4 | $257K | Hold |
2,399
| – | – | ﹤0.01% | 2040 |
|
|
2024
Q3 | $240K | Hold |
2,399
| – | – | ﹤0.01% | 2012 |
|
|
2024
Q2 | $202K | Sell |
2,399
-1
| -0% | -$80 | ﹤0.01% | 2034 |
|
|
2024
Q1 | $175K | Sell |
2,400
-202
| -8% | -$14.9K | ﹤0.01% | 2118 |
|
|
2023
Q4 | $186K | Sell |
2,602
-26
| -1% | -$1.53K | ﹤0.01% | 2124 |
|
|
2023
Q3 | $157K | Sell |
2,628
-76
| -3% | -$5K | ﹤0.01% | 2114 |
|
|
2023
Q2 | $195K | Sell |
2,704
-68
| -2% | -$5.1K | ﹤0.01% | 1942 |
|
|
2023
Q1 | $204K | Buy |
2,772
+937
| +51% | +$66.6K | ﹤0.01% | 1847 |
|
|
2022
Q4 | $123K | Sell |
1,835
-1,902
| -51% | -$124K | ﹤0.01% | 2153 |
|
|
2022
Q3 | $201K | Hold |
3,737
| – | – | ﹤0.01% | 1756 |
|
|
2022
Q2 | $208K | Sell |
3,737
-27
| -0.7% | -$1.53K | ﹤0.01% | 1767 |
|
|
2022
Q1 | $264K | Buy |
3,764
+324
| +9% | +$23.5K | ﹤0.01% | 1723 |
|
|
2021
Q4 | $331K | Buy |
3,440
+728
| +27% | +$67.3K | ﹤0.01% | 1748 |
|
|
2021
Q3 | $236K | Hold |
2,712
| – | – | ﹤0.01% | 1805 |
|
|
2021
Q2 | $222K | Hold |
2,712
| – | – | ﹤0.01% | 1738 |
|
|
2021
Q1 | $258K | Sell |
2,712
-843
| -24% | -$79.7K | ﹤0.01% | 1637 |
|
|
2020
Q4 | $221K | Buy |
3,555
+719
| +25% | +$41K | ﹤0.01% | 1783 |
|
|
2020
Q3 | $169K | Hold |
2,836
| – | – | ﹤0.01% | 1725 |
|
|
2020
Q2 | $198K | Buy |
2,836
+571
| +25% | +$36.2K | ﹤0.01% | 1534 |
|
|
2020
Q1 | $103K | Hold |
2,265
| – | – | ﹤0.01% | 1595 |
|
|
2019
Q4 | $147K | Hold |
2,265
| – | – | ﹤0.01% | 1504 |
|
|
2019
Q3 | $141K | Hold |
2,265
| – | – | ﹤0.01% | 1435 |
|
|
2019
Q2 | $161K | Hold |
2,265
| – | – | ﹤0.01% | 1352 |
|
|
2019
Q1 | $178K | Sell |
2,265
-10
| -0.4% | -$758 | ﹤0.01% | 1241 |
|
|
2018
Q4 | $193K | Hold |
2,275
| – | – | ﹤0.01% | 1224 |
|
|
2018
Q3 | $390K | Buy |
2,275
+149
| +7% | +$22.5K | ﹤0.01% | 995 |
|
|
2018
Q2 | $275K | Buy |
2,126
+361
| +20% | +$40.3K | ﹤0.01% | 1083 |
|
|
2018
Q1 | $182K | Hold |
1,765
| – | – | ﹤0.01% | 1249 |
|
|
2017
Q4 | $151K | Buy |
1,765
+576
| +48% | +$49.9K | ﹤0.01% | 1345 |
|
|
2017
Q3 | $101K | Hold |
1,189
| – | – | ﹤0.01% | 1391 |
|
|
2017
Q2 | $90K | Buy |
1,189
+157
| +15% | +$11K | ﹤0.01% | 1429 |
|
|
2017
Q1 | $68K | Hold |
1,032
| – | – | ﹤0.01% | 1592 |
|
|
2016
Q4 | $65K | Hold |
1,032
| – | – | ﹤0.01% | 1557 |
|
|
2016
Q3 | $66K | Buy |
1,032
+117
| +13% | +$8.59K | ﹤0.01% | 1492 |
|
|
2016
Q2 | $68K | Hold |
915
| – | – | ﹤0.01% | 1352 |
|
|
2016
Q1 | $61K | Hold |
915
| – | – | ﹤0.01% | 1352 |
|
|
2015
Q4 | $62K | Buy |
915
+628
| +219% | +$38.8K | ﹤0.01% | 1331 |
|
|
2015
Q3 | $15K | Buy |
287
+132
| +85% | +$8.01K | ﹤0.01% | 1640 |
|
|
2015
Q2 | $10K | Hold |
155
| – | – | ﹤0.01% | 1382 |
|
|
2015
Q1 | $7K | Buy |
+155
| New | +$5.94K | ﹤0.01% | 1612 |
|
Other funds holding LGND
JT
CAM
Zurich Cantonal Bank's LGND Position: Q2 2026 in Review
Zurich Cantonal Bank increased its Ligand Pharmaceuticals (LGND) stake by 38% in Q2 2026, buying an estimated $280K and bringing the position to 4,311 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1357.
Zurich Cantonal Bank first reported a position in LGND in Q1 2015 and has held it in 46 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Zurich Cantonal Bank held 4,311 shares of Ligand Pharmaceuticals worth $1.36M as of Q2 2026.
- Zurich Cantonal Bank bought 1,190 Ligand Pharmaceuticals shares in Q2 2026, an estimated $280K.
- Ligand Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1357 holding.
- Zurich Cantonal Bank first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 46 quarters since.
- 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.